3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Classical hematology
1
Conditions
Venous Thromboembolism
6
Venous Thrombosis
5
Neoplasms
5
Pulmonary Embolism
4
Neoplasm Metastasis
2
Intracranial Thrombosis
2
Thrombosis
1
Thromboprophylaxis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Mesenteric Ischemia
1
Lymphoma
1
Hematologic Neoplasms
1
Interventions
Dexamethasone
20
Melphalan
13
Thalidomide
10
Bortezomib
10
Lenalidomide
8
Cyclophosphamide
8
Prednisone
6
Filgrastim
6
Doxorubicin
6
Vincristine
5
Epoetin Alfa
5
pomalidomide
3
Zoledronic Acid
3
Peripheral Blood Stem Cell Transplantation
3
Idarubicin
3
carfilzomib
2
Vorinostat
2
Radiotherapy
2
Interferon-alpha
2
Granulocyte Colony-Stimulating Factor
2
Early Intervention, Educational
2
Darbepoetin alfa
2
Carmustine
2
Calcium Dobesilate
2
Busulfan
2
valspodar
1
sargramostim
1
oblimersen
1
liposomal doxorubicin
1
isatuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms, Plasma Cell
×
apixaban
×
Clear all
NCT02066454
2025-08-13
MYELAXAT
University Hospital, Grenoble
Phase 3
Completed
108 enrolled